(PQA4) Point-of-Care Test of Exposure to Hepatocellular Carcinoma Risk by V-Chip

描述（由申请人提供）：（PQA4）肝细胞癌风险暴露的V-Chip即时检测HCC风险协同作用的潜在机制可能为高危人群提供有效和准确的HCC预防策略。暴露于环境或生活方式危险因素的人群同时表现出HCC发展的发生率增加。然而，HCC的大部分负担与低收入人群有关，在乙型肝炎病毒（HBV）感染流行的地区报告的发病率最高。因此，需要开发一种准确、定量、低成本的技术来快速检测生物标志物，以进行HCC风险评估。在此，我们提出了一种基于elisa的新技术平台，即多路体积条形图芯片（V- chip），用于检测血液样本中的生物标志物。所提出的v型芯片是基于微流控技术的。集成的容量读出，基于过氧化氢酶和过氧化氢之间反应产生的氧的测量，允许生物标志物的快速ELISA定量，并在V- Chip上提供可视化的条形图，而无需任何仪器，数据处理或图形绘图的帮助。V-Chip的准确性将在HCC病例和对照中使用标准ELISA检测进行验证。基于流行病学危险因素和V-chip上的生物标志物，我们将建立一个风险预测模型，以预测一个人在未来5年和10年内发生HCC的可能性，以及如果患者的可修改危险因素发生变化，风险降低的可能性。这就给预测V带来了风险

DESCRIPTION (provided by applicant): (PQA4) Point-of-Care Test of Exposure to Hepatocellular Carcinoma Risk by V-Chip Underlying mechanisms for synergisms of HCC risks may provide efficient and accurate HCC prevention strategies for high-risk individuals. People exposed to environmental or life-style risk factors simultaneously exhibit the increased incidence of HCC development. However, most of the burden of HCC is associated with the group of people with low income, with the highest incidence rates reported in regions where infection with hepatitis B virus (HBV) is endemic. Therefore, developing an accurate, quantitative, and also low-cost technology for the rapid detection of biomarkers is required for HCC risk assessment. Herein, we propose an ELISA-based new technology platform, the multiplexed volumetric bar-chart chip (V- Chip), to detect biomarkers in blood samples. The proposed V-Chip is based on microfluidics technology. The integrated volumetric readouts, based on measurements of oxygen generated by a reaction between catalase and hydrogen peroxide, allow rapid ELISA quantitation of biomarkers and provide visualized bar charts on V- Chip without any assistance from instruments, data processing, or graphic plotting. The accuracy of the V-Chip will be validated in HCC cases and controls using standard ELISA assay. Based on epidemiological risk factors and biomarkers on V-chip, we will develop a risk prediction model to predict a person's probability of developing HCC in the next 5 and 10 years based on current risk profiles as well as risk reduction if the patient's modifiable risk factors change. This risks prediction V chip is particularly suitable for the application in resource-limited areas with higher HCC incidence. Patients can use V-Chip in home and personally monitor cirrhosis or HBV/HCV development by themselves, which may bring potential HCC patients to hospital and professionals earlier and thus greatly reduced the costs and risks of HCC.